ACTR10

Across TCGA pan-cancer cohorts, ACTR10 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ACTR10’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACTR10 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTR10 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, HNSC, and KIRC are the cancer types where ACTR10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTR10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.089	<.001	9	view →
HNSC	Female	III,IV	+0.570	<.001	8	view →
KIRC	All	II,III,IV	−0.406	<.001	8	view →
CHOL	Male	All	+1.536	<.001	5	view →
KICH	Female	All	−0.801	<.001	5	view →
THCA	Male	III,IV	−0.288	.002	5	view →
COAD	All	All	−0.338	.012	3	view →
READ	Female	All	−0.751	.016	2	view →
UCEC	All	All	−0.710	.001	2	view →
ESCA	All	All	+0.507	.004	2	view →
LUSC	All	III,IV	−0.405	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ACTR10–LIHC

Open the LIHC breakdown →